Pfizer
add_icon

Pfizer

4,591.00
-132.30
(-2.80%)
Market Cap
21,002.78 Cr
PE Ratio
25.75
Volume
7,285.00
Day High - Low
4,723.30 - 4,569.00
52W High-Low
5,993.00 - 3,701.00
hide
Key Fundamentals
Add Ratio
split_icon_default
Market Cap
21,002.78 Cr
EPS
136.46
PE Ratio
25.75
PB Ratio
5.62
Book Value
841.20
EBITDA
912.50
Dividend Yield
3.49 %
Industry
Healthcare
Return on Equity
18.20
Debt to Equity
0.01
Analyst Rating and Forecast
- By Refinitiv from4 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+50.00 %
+50.00 %
Hold
Hold+50.00 %
+50.00 %
Sell
Sell0.0 %
0.0 %
Forecast For
Actual

Company News

View All News
Caret
neutral
Pfizer Limited announces key senior management changes effective February 1, 2026, including appointment of Nilesh Pendse as Category Lead – Vaccines and organizational restructuring across business divisions.
negative
Pfizer Limited receives significantly higher GST demand order of ₹8.79 crores from West Bengal authorities for FY2018-23, plans to appeal against the order citing it as non-maintainable.
neutral
Ms. Aditi Mehta, Category Lead-Vaccines at Pfizer Limited, has resigned from her position effective January 2, 2026, to pursue opportunities outside the company.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,631.90
#1 3,91,547.47
37.40
#1 54,729.00
9.71
#1 10,980
2.89
32.48
6,011.50
1,59,586.44
64.87
9,712.00
18.67
2,191
35.10
31.96
3,932.20
1,33,083.52
63.64
11,539.40
6.99
1,911
30.46
51.26
1,315.00
1,06,221.99
20.39
28,409.50
7.12
5,291
3.71
16.66
1,235.60
1,03,126.93
18.39
33,741.20
16.73
5,725
-15.28
53.53
2,137.20
97,627.04
22.75
22,909.50
13.74
3,306
#1 72.75
49.85
882.00
88,749.84
#1 17.70
23,511.00
18.55
4,615
34.60
39.82
2,107.60
87,002.80
49.98
12,744.20
#1 20.90
2,007
-21.05
41.23
5,750.50
68,755.85
28.60
13,458.30
3.70
2,216
10.98
54.24
1,132.50
65,775.78
19.45
32,345.60
9.43
3,484
3.81
37.32
Growth Rate
Revenue Growth
3.37 %
Net Income Growth
39.23 %
Cash Flow Change
156.87 %
ROE
18.72 %
ROCE
14.12 %
EBITDA Margin (Avg.)
8.20 %

Yearly Financial Results

Annual Financials
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
Revenue
1,921
2,103
2,067
2,083
2,249
2,336
2,320
2,674
2,526
2,374
2,454
2,745
Expenses
1,470
1,586
1,617
1,468
1,516
1,579
1,526
1,775
1,616
1,558
1,541
1,562
EBITDA
450
517
450
615
733
757
793
898
910
816
913
1,183
Operating Profit %
21 %
21 %
18 %
25 %
27 %
27 %
32 %
32 %
33 %
29 %
32 %
34 %
Depreciation
131
124
63
66
71
103
109
115
106
62
61
60
Interest
1
1
1
0
1
11
15
11
13
15
8
10
Profit Before Tax
238
402
517
548
660
643
669
773
824
746
1,016
1,113
Tax
138
179
180
188
231
133
171
160
200
195
249
282
Net Profit
100
223
337
360
429
509
498
613
624
551
768
839
EPS in ₹
15.26
66.66
73.61
78.70
93.78
111.28
108.77
133.89
136.38
119.22
136.46
183.50

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
2,612
2,914
3,261
3,690
3,940
4,405
3,266
3,901
4,001
4,229
4,911
Fixed Assets
944
895
902
950
886
973
894
869
749
713
724
Current Assets
1,253
1,630
2,051
2,417
2,715
3,048
1,925
2,397
2,493
2,738
3,513
Capital Work in Progress
13
3
15
1
0
1
3
1
8
0
8
Investments
0
4
0
0
0
0
0
0
0
0
0
Other Assets
1,655
2,011
2,343
2,739
3,054
3,432
2,369
3,030
3,244
3,516
4,180
Total Liabilities
2,612
2,914
3,261
3,690
3,940
4,405
3,266
3,901
4,001
4,229
4,911
Current Liabilities
606
759
780
954
892
873
774
853
657
547
570
Non Current Liabilities
32
36
62
52
37
137
99
183
136
87
124
Total Equity
1,973
2,118
2,419
2,683
3,011
3,396
2,393
2,864
3,207
3,596
4,217
Reserve & Surplus
1,927
2,072
2,373
2,637
2,966
3,350
2,347
2,819
3,162
3,550
4,172
Share Capital
46
46
46
46
46
46
46
46
46
46
46

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
181
-417
-4
-17
23
1,690
-1,613
-88
-26
75
383
Investing Activities
68
-701
-250
-238
35
1,530
-469
-575
-36
54
-71
Operating Activities
114
346
329
332
98
323
427
667
356
257
660
Financing Activities
-1
-62
-83
-110
-110
-164
-1,571
-181
-346
-235
-205

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Promoter
63.92 %
63.92 %
63.92 %
63.92 %
63.92 %
63.92 %
63.92 %
63.92 %
63.92 %
63.92 %
63.92 %
63.92 %
63.92 %
63.92 %
63.92 %
63.92 %
63.92 %
63.92 %
63.92 %
63.92 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
2.82 %
0.00 %
3.33 %
3.22 %
3.54 %
2.75 %
2.18 %
2.39 %
2.60 %
2.71 %
DIIs
13.08 %
8.98 %
8.98 %
8.84 %
8.57 %
7.91 %
14.85 %
14.93 %
14.89 %
14.89 %
15.01 %
15.15 %
15.33 %
15.84 %
16.03 %
16.79 %
17.10 %
17.23 %
17.10 %
17.05 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
15.03 %
14.11 %
14.11 %
14.25 %
14.19 %
14.08 %
13.94 %
13.71 %
13.70 %
13.69 %
13.61 %
13.21 %
12.90 %
12.55 %
12.15 %
12.12 %
12.34 %
12.02 %
12.08 %
11.93 %
Others
7.97 %
12.98 %
12.98 %
12.99 %
13.32 %
14.08 %
7.29 %
7.43 %
7.49 %
7.50 %
4.64 %
7.72 %
4.52 %
4.46 %
4.35 %
4.41 %
4.45 %
4.43 %
4.29 %
4.39 %
No of Share Holders
1,45,980
1,21,153
1,21,153
1,26,808
1,25,287
1,23,449
1,22,028
1,17,950
1,17,194
1,15,988
1,16,948
1,12,456
1,09,214
1,06,098
98,824
1,05,015
1,08,261
1,03,222
1,03,480
1,00,933

Dividend History

Annual Cash Flows 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Dividend Per Share (₹) 20 20 22.5 330 35 35 70 35 165 0.00
Dividend Yield (%) 0.92 0.6 0.56 7.29 0.8 1 1.67 0.87 3.49 0.00

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
13 Aug 2021 DIVIDEND Dividend
₹ 5.00 /share
11 Aug 2021 5,251.65 5,820.45
13 Aug 2021 DIVIDEND Dividend
₹ 30.00 /share
11 Aug 2021 5,251.65 5,820.45
19 Aug 2022 DIVIDEND Dividend
₹ 35.00 /share
18 Aug 2022 4,261.65 4,215.30
20 Feb 2022 DIVIDEND Dividend
₹ 30.00 /share
19 Sept 2022 4,277.45 4,346.40
11 Aug 2023 DIVIDEND Dividend
₹ 5.00 /share
11 Aug 2023 3,772.20 4,038.75
11 Aug 2023 DIVIDEND Dividend
₹ 35.00 /share
11 Aug 2023 3,772.20 4,038.75
21 Aug 2024 DIVIDEND Dividend
₹ 35.00 /share
21 Aug 2024 4,335.90 5,901.90
28 Aug 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
28 Aug 2024 5,842.95 5,862.80
28 Oct 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
28 Oct 2024 5,673.00 5,308.70
31 Jan 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
31 Jan 2025 4,784.65 4,516.55
19 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
19 May 2025 4,249.90 4,411.35
09 Jul 2025 DIVIDEND Dividend
₹ 30.00 /share
09 Jul 2025 4,411.35 5,851.00
09 Jul 2025 DIVIDEND Dividend
₹ 35.00 /share
09 Jul 2025 4,411.35 5,851.00
21 Jul 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
21 Jul 2025 4,411.35 5,319.50
13 Aug 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
13 Aug 2025 5,052.80 5,087.05
12 Nov 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
12 Nov 2025 5,207.60 4,996.20

Announcements

Announcement under Regulation 30 (LODR)-Change in Management3 days ago
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 09, 2026
Closure of Trading WindowDec 29, 2025
Disclosure under Regulation 30A of LODRDec 28, 2025
Intimation Pursuant To Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015.Dec 24, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementDec 23, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseDec 19, 2025
Exclusive Supply And Marketing Agreement With Cipla Limited For Certain Products.Dec 19, 2025
Board Meeting Outcome for Outcome Of Board Meeting - Unaudited Financial Results For The Quarter And Half Year Ended September 30 2025Nov 12, 2025
Board Meeting Intimation for Board Meeting To Consider And Approve The Unaudited Financial Results For The Quarter And Half Year Ended September 30 2025.Nov 03, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 08, 2025
Closure of Trading WindowSep 29, 2025
Board Meeting Outcome for Outcome Of Board Meeting - Unaudited Financial Results For The Quarter Ended June 30 2025 Held Today August 13 2025Aug 13, 2025
Outcome Of Board Meeting - Unaudited Financial Results For The Quarter Ended June 30 2025 Held Today August 13 2025Aug 13, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 11, 2025
Launch Of Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed) I.P. 20 - Valent (PCV20)Aug 11, 2025
Board Meeting Intimation for Board Meeting To Consider And Approve The Unaudited Financial Results For The Quarter Ended June 30 2025Aug 07, 2025
Shareholder Meeting / Postal Ballot-Scrutinizers ReportJul 22, 2025
Shareholder Meeting / Postal Ballot-Outcome of AGMJul 21, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 07, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementJul 02, 2025
Letter To Shareholders Providing The Weblink For Accessing The Annual Report.Jun 30, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 30, 2025
Closure of Trading WindowJun 30, 2025
Business Responsibility and Sustainability Reporting (BRSR)Jun 29, 2025
Reg. 34 (1) Annual Report.Jun 29, 2025
Notice Of The 74Th Annual General Meeting Of The Company.Jun 29, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 23, 2025
Appointment Of Cost And Secretarial AuditorMay 19, 2025
Intimation Of Date Of Annual General MeetingMay 19, 2025
Corporate Action-Board approves DividendMay 19, 2025
Board Meeting Outcome for Outcome Of Board MeetingMay 19, 2025
Board Meeting Intimation for Board Meeting To Consider And Approve The Audited Financial Results For The Quarter And Financial Year Ended March 31 2025.May 13, 2025
Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2Apr 29, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 11, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementApr 01, 2025
Closure of Trading WindowMar 31, 2025
Update On Transfer And Assignment Of PfizerS Unexpired Leasehold Rights In The Land Situated At Plot No. 16 Trans Thane Creek Industrial Area Turbhe Thane And Sale Of Structures And Buildings Constructed Thereon To Zoetis Pharmaceutical Research Private Mar 29, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Mar 19, 2025
Board Meeting Outcome for Marketing And Supply Agreement With Mylan Pharmaceuticals Private LimitedFeb 21, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateFeb 14, 2025
Receipt Of GST Order Levying Tax Demand And PenaltyFeb 05, 2025
Receipt Of GST Order Levying Tax Demand And PenaltyFeb 05, 2025
Receipt Of GST Order For A Tax Demand Interest And PenaltyFeb 04, 2025
Levy Of Tax Demand And PenaltyFeb 03, 2025
Integrated Filing (Financial)Feb 01, 2025
Update On Transfer And Assignment Of PfizerS Unexpired Leasehold Rights In The Land Situated At Plot No. 16 Trans Thane Creek Industrial Area Turbhe Thane To Zoetis Pharmaceutical Research Private LimFeb 01, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementJan 31, 2025
Board Meeting Outcome for Outcome Of The Board Meeting- Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2024Jan 31, 2025
Board Meeting Intimation for Board Meeting To Consider And Take On Record The Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2024Jan 24, 2025

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
ICICI Prudential Smallcap Fund Direct Plan-Growth
2.13%
71398
0.43%
0.74%
HDFC Pharma And Healthcare Fund Direct - Growth
0.00%
-48556
-1.20%
-1.29%
Tata Flexi Cap Fund Direct - Growth
0.30%
-37837
-0.52%
-1.13%
ICICI Prudential Value Direct-Growth
0.28%
18058
0.01%
0.28%
LIC MF Consumption Fund Direct-Growth
1.24%
13149
1.24%
1.24%
Bajaj Finserv Multi Cap Fund Direct-Growth
0.00%
-9132
-0.42%
-0.79%
UTI Dividend Yield Fund Direct-Growth
1.19%
-5781
-0.07%
-0.14%
UTI MNC Fund Direct-Growth
1.10%
2919
0.06%
0.02%
Samco Multi Asset Allocation Fund Direct-Growth
0.24%
1802
0.24%
-0.14%
WhiteOak Capital Pharma and Healthcare Fund Direct - Growth
1.47%
995
0.08%
-0.05%
Samco Multi Cap Fund Direct-Growth
1.26%
-816
-0.07%
0.02%
UTI Nifty Midsmallcap 400 Momentum Quality 100 Index Fund Direct-Growth
0.00%
-742
-0.39%
-0.41%
Angel One Nifty Total Market Momentum Quality 50 Index Fund Direct - Growth
0.00%
-519
-0.78%
0.00%
Navi Nifty Smallcap250 Momentum Quality 100 Index Fund Direct - Growth
0.00%
-486
-1.01%
-1.03%
NJ ELSS Tax Saver Scheme Direct - Growth
3.61%
412
0.04%
-0.11%
DSP Nifty Smallcap250 Quality 50 Index Fund Direct - Growth
1.62%
-341
-0.07%
-0.10%
JioBlackRock Nifty Smallcap 250 Index Fund Direct - Growth
0.38%
263
0.00%
-0.01%
Nippon India Nifty 500 Equal Weight Index Fund Direct-Growth
0.20%
-185
0.00%
-0.01%
ICICI Prudential Nifty Smallcap 250 Index Fund Direct - Growth
0.38%
-100
0.00%
-0.01%
SBI Nifty Smallcap 250 Index Fund Direct - Growth
0.38%
-81
0.00%
0.00%
Tata Nifty MidSmall Healthcare Index Fund Direct - Growth
1.41%
-66
0.01%
-0.06%
Nippon India Nifty Smallcap 250 Index Fund Direct - Growth
0.38%
56
0.00%
0.00%
Motilal Oswal Nifty 500 Index Fund Direct - Growth
0.04%
51
0.00%
0.00%
Motilal Oswal Nifty Smallcap 250 Index Fund Direct - Growth
0.38%
-48
0.00%
-0.01%
HDFC Nifty Smallcap 250 Index Fund Direct-Growth
0.38%
-31
0.00%
0.00%

Technical Indicators

RSI(14)
Neutral
38.81
ATR(14)
Volatile
98.86
STOCH(9,6)
Oversold
17.14
STOCH RSI(14)
Neutral
25.55
MACD(12,26)
Bearish
-19.17
ADX(14)
Strong Trend
27.62
UO(9)
Bearish
46.93
ROC(12)
Downtrend But Slowing Down
-3.02
WillR(14)
Neutral
-65.29

About Pfizer

Pfizer Limited is an Indian pharmaceutical company engaged in manufacturing, marketing, trading, and exporting pharmaceutical products. It has a manufacturing facility in Goa and works with contract manufacturers across India. The company offers a diverse portfolio of products including vaccines, anti-infectives, cardiac medications, pain relief, maternal nutrition, gastrointestinal treatments, contraceptives,...more
Chairperson NamePradip P Shah